Back

The clinical value of estimated small dense LDL in primary and secondary prevention

29 August 2026 (15:15 - 16:00)
Organised by: Logo
Congress Presentation Part of: Clinico-metabolic phenotyping and heart disease (2) Biomarkers ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Dimitrios Delialis

Alexandra University Hospital, Athens (Greece)

6 More presentations in this session

Presentation thumbnail
Clinico-metabolic phenotyping predicts long-term mortality in at-risk and pre-clinical heart failure: a machine learning analysis
Miss A. Mavromanoli (Mainz, DE)
Abstract
Presentation thumbnail
Understanding and predicting CVD in Singapore: socioeconomic determinants and a non-lab risk score across two cohorts
Professor D. Hausenloy (Singapore, SG)
Abstract
Presentation thumbnail
Prediction and cumulative incidence of in-hospital bleeding among acutely ill medical patients receiving pharmacologic VTE prophylaxis based on the IMPROVE-BRS: a retrospective single-center cohort
Doctor J. Catangui (Manila, PH)
Abstract
Presentation thumbnail
Primary care detection reveals substantial cumulative LDL-C exposure in underrecognized heterozygous FH
Doctor H. Leskaroska (Skopje, MK)
Abstract
Presentation thumbnail
Incremental value of ADMA beyond classical risk factors for cardiometabolic risk prediction in ischemic heart disease
Doctor S. Akhmedov (Tashkent, UZ)
Abstract

Access the full session

Session thumbnail
Clinico-metabolic phenotyping and heart disease (2)

The Event

Event poster

ESC Congress 2026

29 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Small dense low-density lipoprotein cholesterol predicts long-term recurrence of coronary artery disease in patients without metabolic dyslipidemia
25 April 2026
thumbnail
Congress Presentation
The added value of ECG on the PREVENT CVD risk score for the prediction of subclinical cardiac disease - insights from Project Baseline Health Study
29 August 2025
thumbnail
Congress Presentation
Efficacy and safety of inclisiran in patients with established cerebrovascular disease: pooled, post hoc analysis of the ORION-9, ORION-10 and ORION-11, phase 3 randomised clinical trials
27 August 2021
thumbnail
Congress Presentation
Cholesterol efflux capacity and subclinical atherosclerosis: is its impact greater in early stages?
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources